Discussion [2/2]
📌DREAMseq study shows order matters in oncogene-mutant melanoma: immunotherapy before targeted therapy
📌Longer follow-up period needed to analyse clinical durability
📌Further studies including patients with brain metastases would also be beneficial
#JournalClub@claudialee_ & guest expert @pdnpdnpdn discussed Tawbi et al. @NEJM https://t.co/908mUaTW69
Relatlimab–nivolumab (anti-LAG3 & anti-PD1) was superior to nivolumab alone in untreated advanced melanoma. Median PFS 10.1 vs 4.6 months, hazard ratio 0.75.
Discussion [1/2]
📌Could rel-nivo benefit non-responders to ipilimumab (anti-CTLA4)-nivolumab (CheckMate-067 study)?
📌If patient is not fit enough for ipi-nivo, consider rel-nivo? Treatment-related adverse events in 59% ipi-nivo patients vs 19% rel-nivo patients
The UCL MBPhD programme is recruiting for Sep 2022 and Sep 2023! Come to our open day from 13:00 – 15:00 on 2 December on MS Teams . See https://t.co/GqOb5pp81E for course info.
Discussion points:
📌 value of registry data from 35 European sites
📌 tricky to differentiate between COVID Sx vs cancer progression Sx?
📌 control group (patients with cancer without COVID) would help interpretation
📌 in practice, Rx adjustments depend on the clinical picture
#JournalClub@tricia_lim97 discussed Pinato et al. @TheLancetOncol https://t.co/GBUnk2u9RN. In ~2.8k patients with cancer, post COVID-19 sequelae associated with worse survival outcomes, however dose and regimen adjustments did not.
Fantastic start to @UCL_MBPhD Journal Club: @Jane_Ganesh presents @NEJM paper “Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel”. 3rd dose prevents infection and may reduce severe disease. Thank you Dr Amit Huppert, lead author joining from @TelAvivUni !
Excited to finally be at the first in-person conference of my PhD (and present my first poster on γδ T cells for the treatment of patient-derived colorectal cancer organoids!) @UCL_MBPhD@CRUKCOLcentre@uclcancer https://t.co/TiPs4h2QED
Congratulations to #MBPhD student @dotalawode and colleagues on their recent review in @JInternMed!
Title: 'Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer’s disease'
@UkdriL@UKDRI@drcionucl@UCLIoN
I'm delighted to share:
Overcoming Pavlovian bias in semantic space
https://t.co/AP7A5cGFZE
It's the first project I started and the last one I finished during my PhD. It never found a home in my thesis.
The results aren't pretty, but I hope someone finds them helpful one day
The @UCL_MBPhD programme application deadline for 2021 and 2022 entry is next Wednesday 17 February!
Further information can be found at the following link: https://t.co/XMClz4Fnlt
Identification of Candidate Parkinson Disease Genes Using Genome-Wide Association Study, Expression, and Epigenetic Data Sets https://t.co/J1yumlil6d @UCL_MBPhD@UCLIoN
Congratulations to all authors of this recent paper in @CellCellPress, including #MBPhD students @dhruva_biswas and @tbkwatkins and #MBPhD alumnus @CharlesSwanton!
Title: 'Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition'